The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Mutant p53 Gain-of-Function in Cancer
Open accessAbstract
In its wild-type form, p53 is a major tumor suppressor whose function is critical for protection against cancer. Many human tumors carry missense mutations in the TP53 gene, encoding p53. Typically, the affected tumor cells accumulate excessive amounts of the mutant p53 protein. Various lines of evidence indicate that, in addition to abrogating the tumor suppressor functions of wild-type p53, the common types of cancer-associated p53 mutations also endow the mutant protein with new activities that can contribute actively to various stages of tumor progression and to increased resistance to anticancer treatments. Collectively, these activities are referred to as mutant p53 gain-of-function. This article addresses the biological manifestations of mutant p53 gain-of-function, the underlying molecular mechanisms, and their possible clinical implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1145 · Cited by 129
Self-citationRetractedMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“However, mutp53 is still susceptible to Mdm2mediated degradation (Haupt et al. 1997; Lukashchuk and Vousden 2007), arguing that the mutations per se do not render p53 immune to the action of Mdm2.”
BackgroundSelf-citationMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 3×
“This does not necessarily imply that cancers with p53 mutations will be more refractory to therapy (see Olivier et al. 2010).”
BackgroundThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Self-citationThe multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,853
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Self-citationYin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., & Wahl, G. M. (1992) · Cell · doi:10.1016/0092-8674(92)90244-7 · Cited by 1,089
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 782
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 666
Self-citationPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Transcriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569 · cited 1×
“However, both p63 and p73 also possess additional, distinct activities, which are not shared with wtp53 and impinge on many important biological processes, most notably development and differentiation (see Beckerman and Prives 2010).”
BackgroundA common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 515
Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F., & Jacks, T. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.019 · Cited by 502
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
Wang, S.-P., Wang, W.-L., Chang, Y.-L., Wu, C.-T., Chao, Y.-C., Kao, S.-H., Yuan, A., Lin, C.-W., Yang, S.-C., Chan, W.-K., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1875 · Cited by 493
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Murphy, M., Ahn, J., Walker, K. K., Hoffman, W. H., Evans, R. M., Levine, A. J., & George, D. L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2490 · Cited by 455
Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 441
Self-citationp53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 439
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
Chemosensitivity linked to p73 function
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 408
Links between Tumor Suppressors
Cordenonsi, M., Dupont, S., Maretto, S., Insinga, A., Imbriano, C., & Piccolo, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00308-8 · Cited by 382
Differentiation plasticity regulated by TGF-β family proteins in development and disease
Derynck, R., & Akhurst, R. J. (2007) · Nature Cell Biology · doi:10.1038/ncb434 · Cited by 382
Werner, H., Karnieli, E., Rauscher, F. J., & LeRoith, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8318 · Cited by 370
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
Mutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269
Wolf, D., Harris, N., & Rotter, V. (1984) · Cell · doi:10.1016/0092-8674(84)90532-4 · Cited by 249
Self-citationGualberto, A., Aldape, K., Kozakiewicz, K., & Tlsty, T. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5166 · Cited by 237
Differentiation plasticity regulated by TGF-|[beta]| family proteins in development and disease
Derynck, R., & Akhurst, R. J. (2007) · Nature · doi:10.1038/ncb0907-1000 · Cited by 227
Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities
Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M. G., Monti, O., Baccarini, A., Del Sal, G., Levrero, M., Sacchi, A., Oren, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201405200 · Cited by 226
Self-citationUbiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
Transcription regulation by mutant p53
Weisz, L., Oren, M., & Rotter, V (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207
Self-citationReactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202
Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells
Weisz, L., Damalas, A., Liontos, M., Karakaidos, P., Fontemaggi, G., Maor-Aloni, R., Kalis, M., Levrero, M., Strano, S., Gorgoulis, V. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2425 · Cited by 199
Self-citationFrazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194
Transcriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human p53
Ludes-Meyers, J. H., Subler, M. A., Shivakumar, C. V., Munoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., & Deb, S. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6009 · Cited by 182
Rotter, V. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.9.2613 · Cited by 161
Self-citationRecent advances in p53 research: an interdisciplinary perspective
Olivier, M., Petitjean, A., Marcel, V, Pétré, A., Mounawar, M., Plymoth, A., de Fromentel, C. C., & Hainaut, P. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2008.69 · Cited by 161
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
Deb, S., Jackson, C. T., Subler, M. A., & Martin, D. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6164-6170.1992 · Cited by 160
Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression
Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 152
Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery
Offer, H., Wolkowicz, R., Matas, D., Blumenstein, S., Livneh, Z., & Rotter, V. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00505-0 · Cited by 150
Self-citationVikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145
Caulín, C., Nguyen, T., Lang, G. A., Goepfert, T. M., Brinkley, B. R., Cai, W., Lozano, G., & Roop, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31721 · Cited by 144
Mutant p53 protein expression interferes with p53-independent apoptotic pathways
Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., & Rotter, V. (1998) · Oncogene · doi:10.1038/sj.onc.1201867 · Cited by 140
Self-citationHsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P. K., Yeargin, J., & Haas, M. (1994) · PubMed Central · Cited by 135
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123
Self-citationTumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes
Scian, M. J., Stagliano, K. E., Deb, D., Ellis, M. A., Carchman, E. H., Das, A., Valerie, K. C., Deb, S. P., & Deb, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207553 · Cited by 120
Modulation of Gene Expression by Tumor-Derived p53 Mutants
Scian, M. J., Stagliano, K. E., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 117
p53, p63 and p73 – solos, alliances and feuds among family members
Moll, U. M., Erster, S. H., & Zaika, A. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00036-1 · Cited by 116
Singer, S., Ehemann, V., Brauckhoff, A., Keith, M., Vreden, S., Schirmacher, P., & Breuhahn, K. (2007) · Hepatology · doi:10.1002/hep.21736 · Cited by 112
p53 Mutations: Gains or losses?
Michalovitz, D., Halevy, O., & Oren, M. (1991) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240450108 · Cited by 107
Self-citationStructural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants
(2007) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)97001-8 · Cited by 106
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1963 · Cited by 95
p73 Suppresses Polyploidy and Aneuploidy in the Absence of Functional p53
Talos, F., Nemajerová, A., Flores, E. R., Petrenko, O., & Moll, U. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.036 · Cited by 94
Lee, Y. I., Lee, S., Das, G. C., Park, U. S., Park, S. M., & Lee, Y. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203694 · Cited by 94
Bossi, G., Marampon, F., Maor-Aloni, R., ZANI, B. M., Rotter, V., Oren, M., Strano, S., Blandino, G., & Sacchi, A. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6161 · Cited by 93
Self-citationMurphy, K. L., Dennis, A. P., & Rosen, J. M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0128com · Cited by 91
The oncogenic roles of p53 mutants in mouse models
Lozano, G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.003 · Cited by 89
Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N., & Rotter, V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4163 · Cited by 88
Self-citationSer392 Phosphorylation Regulates the Oncogenic Function of Mutant p53
Yap, D., Hsieh, J.-K., Zhong, S., Heath, V., Gusterson, B. A., Crook, T., & Lü, X. (2004) · Cancer Research · doi:10.1158/0008-5472.can-1305-2 · Cited by 87
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3
Wong, R. P. C., Tsang, W. P., Chau, P. Y., Co, N. N., Tsang, T. Y., & Kwok, T. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0336 · Cited by 87
Lányi, Á., Deb, D., Seymour, R. C., Ludes-Meyers, J. H., Subler, M. A., & Deb, S. (1998) · Oncogene · doi:10.1038/sj.onc.1201857 · Cited by 87
Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function
Yan, W., & Chen, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900994200 · Cited by 80
Mutant p53 proteins bind DNA in a DNA structure-selective mode
hler, T. G. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki252 · Cited by 76
Kalo, E., Buganim, Y., Shapira, K. E., Besserglick, H., Goldfinger, N., Weisz, L., Stambolsky, P., Henis, Y. I., & Rotter, V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00374-07 · Cited by 71
Self-citationAlbor, A., Kaku, S., & Kulesz-Martin, M. F. (1998) · PubMed · Cited by 70
Agostino, S. D., Cortese, G., Monti, O., Dell’Orso, S., Sacchi, A., Eisenstein, M., Citro, G., Strano, S., & Blandino, G. (2008) · Cell Cycle · doi:10.4161/cc.7.21.6995 · Cited by 68
Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53
Haupt, S., Agostino, S. D., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., Blandino, G., & Haupt, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4010 · Cited by 67
Yan, W., Liu, G., Scoumanne, A., & Chen, X. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0810 · Cited by 66
p53 Increases Experimental Metastatic Capacity of Murine Carcinoma Cells
Pohl, J., Goldfinger, N., Radler‐Pohl, A., Rotter, V., & Schirrmacher, V. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.5.2078 · Cited by 62
Self-citationHeinlein, C., Krepulat, F., Löhler, J., Speidel, D., Deppert, W., & Tolstonog, G. V. (2007) · International Journal of Cancer · doi:10.1002/ijc.23317 · Cited by 59
Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
Loging, W., & Reisman, D. (1999) · PubMed · Cited by 58
Iwamoto, K. S., Mizuno, T., Ito, T., Tsuyama, N., Kyoizumi, S., & Seyama, T. (1996) · PubMed · Cited by 57
Dong, P., Tada, M., Hamada, J., Nakamura, A., Moriuchi, T., & Sakuragi, N. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9084-8 · Cited by 56
Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
El-Hizawi, S., Lagowski, J. P., Kulesz-Martin, M. F., & Albor, A. (2002) · PubMed · Cited by 55
Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53
Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., & Oren, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209061 · Cited by 50
Self-citationGain of Function of p53 Cancer Mutants in Disrupting Critical DNA Damage Response Pathways
Song, H., & Xu, Y. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4456 · Cited by 50
Restle, A., Färber, M., Baumann, C., Böhringer, M., Scheidtmann, K. H., Müller-Tidow, C., & Wiesmüller, L. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn503 · Cited by 49
Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
Gurova, K. V., Rokhlin, O. W., Budanov, A. V., Burdelya, L., Chumakov, P. M., Cohen, M. B., & Gudkov, A. V. (2003) · PubMed · Cited by 49
Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells.
Peled, A., Zipori, D., & Rotter, V. (1996) · PubMed · Cited by 48
Self-citationFrequent p53 mutations in chemically induced murine fibrosarcoma.
Halevy, O., Rödel, J., Peled, A., & Oren, M. (1991) · PubMed · Cited by 45
Self-citationLotem, J., & Sachs, L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9672 · Cited by 42
Lavra, L., Ulivieri, A., Rinaldo, C., Dominici, R., Volante, M., Luciani, E., Bartolazzi, A., Frasca, F., Soddu, S., & Sciacchitano, S. (2008) · The Journal of Pathology · doi:10.1002/path.2510 · Cited by 36
Buganim, Y., Kalo, E., Brosh, R., Besserglick, H., Nachmany, I., Rais, Y., Stambolsky, P., Tang, X., Milyavsky, M., Shats, I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0916 · Cited by 34
Self-citationMutant p53 gain of function: The NF-Y connection
Peart, M. J., & Prives, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.014 · Cited by 34
Duan, W., Ding, H., Subler, M. A., Zhu, W., Zhang, H., Stoner, G. D., Windle, J. J., Otterson, G. A., & Villalona-Calero, M. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205909 · Cited by 32
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Donzelli, S., Biagioni, F., Fausti, F., Strano, S., Fontemaggi, G., & Blandino, G. (2008) · Current Genomics · doi:10.2174/138920208784340713 · Cited by 22
Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice
Duan, W., Gao, L., Jin, D., Otterson, G. A., & Villalona-Calero, M. A. (2007) · Transgenic Research · doi:10.1007/s11248-007-9154-3 · Cited by 18
Duan, W., Gao, L., Wu, X., Hade, E. M., Gao, J., Ding, H., Barsky, S. H., Otterson, G. A., & Villalona-Calero, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005563 · Cited by 13
THIERS, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70918-3 · Cited by 11
董, 培. (2008) · Medical Entomology and Zoology · Cited by 7
Cell type‐specific regulation of calmodulin 2 expression by mutant p53
Knaup, K. X., & Roemer, K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.05.052 · Cited by 6
Cited by
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Predicting the functional impact of protein mutations: application to cancer genomics
Reva, B., Antipin, Y., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr407 · Cited by 2,002
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
The hnRNP family: insights into their role in health and disease
Geuens, T., Bouhy, D., & Timmerman, V. (2016) · Human Genetics · doi:10.1007/s00439-016-1683-5 · Cited by 1,093
Metadata
- Authors
- Oren, M., & Rotter, V.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2009-12-16
- Volume
- 2
- Issue
- 2
- Pages
- a001107-a001107
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2112396116
- Cited by
- 753
- References
- 105
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.